Context: Introduction of additional new agents targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) has completely modified the systemic treatment of metastatic renal cell carcinoma (mRCC) during the last years.
Objective: A comprehensive (nonsystematic) review to determine the suggested sequence or combinations for the systemic treatment of mRCC.
Evidence Acquisition: PubMed and abstracts from main conferences up to December 2018 were reviewed to retrieve the current evidence for treatment of mRCC. Search terms included renal cell carcinoma, systemic therapy, targeted therapy (TT), and immunotherapy.
Evidence Synthesis: Marked advances in the treatment of mRCC have been made with novel VEGFR tyrosine kinase inhibitors and multiple ICIs that have been included in the current treatment paradigm of mRCC. Remarkable advance has been made with the combination of double checkpoint blockade. The combination of ipilimumab and nivolumab compared with sunitinib has shown to increase the overall survival in the intermediate- and poor-risk patients based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model.
Conclusions: Double checkpoint blockade with ipilimumab and nivolumab has reported overall survival benefit in IMDC intermediate- and poor-risk patients, providing a durable response for a subset of patients. VEGF inhibitors remain the standard of care for favorable-risk patients in the first line. In the immediate future, more consolidated data on combination of VEGF-TT plus ICIs may show similar robust benefit with different safety profiles.
Patient Summary: Multiple drugs and sequences are now accepted as effective treatment for metastatic renal cell carcinoma (mRCC). Combination of immune checkpoint inhibitors has shown to increase the overall survival in treatment-naïve mRCC patients. Combinations of immunotherapy and antiangiogenics may be another option in the near future. Outcomes of the first line will determine the sequence, although the best sequence has yet to be defined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euo.2019.06.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An integrative analysis reveals cancer risk associated with artificial sweeteners.
J Transl Med
January 2025
Medical College of YiChun University, Xuefu Road No 576, Yichun, 336000, Jiangxi, People's Republic of China.
Background: Artificial sweeteners (AS) have been widely utilized in the food, beverage, and pharmaceutical industries for decades. While numerous publications have suggested a potential link between AS and diseases, particularly cancer, controversy still surrounds this issue. This study aims to investigate the association between AS consumption and cancer risk.
View Article and Find Full Text PDFCASP5 associated with PANoptosis promotes tumorigenesis and progression of clear cell renal cell carcinoma.
Cancer Cell Int
January 2025
Institute for Genome Engineered Animal Models of Human Diseases, National Center of Genetically Engineered Animal Models for International Research, Dalian Medical University, 9 West Section Lvshun South Road, Dalian, 116044, China.
Clear cell renal cell carcinoma (ccRCC) is a globally severe cancer with an unfavorable prognosis. PANoptosis, a form of cell death regulated by PANoptosomes, plays a role in numerous cancer types. However, the specific roles of genes associated with PANoptosis in the development and advancement of ccRCC remain unclear.
View Article and Find Full Text PDFIdentifying ADME-related gene signature for immune landscape and prognosis in KIRC by single-cell and spatial transcriptome analysis.
Sci Rep
January 2025
Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Kidney renal clear cell carcinoma (KIRC) is the most prevalent subtype of kidney cancer. Although multiple therapeutic agents have been proven effective in KIRC, their clinical application has been hindered by a lack of reliable biomarkers. This study focused on the prognostic value and function of drug absorption, distribution, metabolism, and excretion- (ADME-) related genes (ARGs) in KIRC to enhance personalized therapy.
View Article and Find Full Text PDFAnalysis of mRNA Pentatricopeptide Repeat Domain 1 as a prospective oncogene in clear cell renal cell carcinoma that accelerates tumor cells proliferation and invasion via the Akt/GSK3β/β-catenin pathway.
Discov Oncol
January 2025
Department of Urology, Beijing TianTan Hospital, Capital Medical University, No. 119 South 4 Ring West Road, Fengtai District, 100070, Beijing, China.
Background: Although pentatricopeptide repeat domain 1 (PTCD1) has been found to modulate mitochondrial metabolic and oxidative phosphorylation, its contribution in the growth of clear cell renal cell carcinoma (ccRCC) remains unknown.
Methods: The Cancer Genome Atlas (TCGA) dataset was utilized to examine the transcriptional alterations, patient characteristics, clinical outcomes, as well as pathway activation of PTCD1. The Weighted Gene Co-expression Network Analysis (WGCNA) was performed to investigate potential genes that associated with PTCD1.
A rare case of a horseshoe kidney with a single left-sided ureter presented with recurrent urinary tract infection.
Saudi Med J
January 2025
From the Department of Surgery (Ayed), from Department of Urology (Alwadai), King Abdullah Hospital, Ministry of Health, Bisha, Kingdom of Saudi Arabia, from the Department of Anatomy (Rezigalla), College of Medicine, University of Bisha.
The horseshoe kidney (HSK) is a common renal abnormality mostly asymptomatic. This may be linked to chromosomal and organ anomalies. A 27-year-old male patient presented with mild recurrent lower abdominal pain associated with dysuria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!